Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Elizabeth Perkins (NPI 1811105398)

Field	Value
Entity Type	Individual
Organization	Elizabeth Perkins
Address	5356 Stadium Trace Pkwy Ste 200
City	Hoover
State	AL
ZIP	35244
Taxonomy	Rheumatology Physician
NPI Enumerated	May 18, 2007

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider’s commercial footprint in public programs is effectively single‑payer: Total Medicare revenue is $2.9M and there is no Medicaid billing on file, so Medicare represents the entire documented public-payor revenue stream for this NPI. That concentration means analyses of utilization and revenue risk should focus on Medicare reimbursement and drug-administration volumes rather than dual‑payer dynamics.

Revenue is highly concentrated in a small set of biologic drug-administration codes: the precomputed top 3 codes (J0129, J3245, J0717) account for 72.4% of the provider’s Medicare revenue, with J0129 contributing $764.2K (26.4%), J3245 $748K (25.9%), and J0717 $580.8K (20.1%). This level of concentration indicates the practice’s financial performance is driven mostly by on‑site biologic/infusion drug administration rather than routine office billing.

The code mix is consistent with a rheumatology practice operating an infusion/administration suite: dominant codes include J0129 (abatacept), J3245 (tildrakizumab), J0717 (certolizumab pegol), Q5104 (infliximab biosimilar), J1745 (infliximab) and J1602 (golimumab). These drug and biosimilar administration codes, together with multiple infusion/chemotherapy administration CPTs appearing in the top codes, suggest substantial on‑site parenteral therapy capacity and a drug‑revenue business model.

Competitive standing by national rank shows above‑typical volumes for several core biologics: J0717 ranks #67 of 848 providers (92th percentile), J0129 ranks #106 of 1221 (91th percentile), and J3245 ranks #39 of 225 (83th percentile), while Q5104 ranks #15 of 178 (92th percentile). Those percentiles indicate a strong national presence in administration of specific biologics, though some related codes like J1745 rank lower (25th percentile), reflecting variation by molecule and potential formulary or sourcing choices.

Several non‑primary procedure codes register as statistical outliers or notably above typical national volume and warrant attention: 96401 is labeled an "extreme outlier, far above typical national volume" with $56.4K (2.0%), 96413 is "notably above typical" with $52.1K (1.8%), and J2920 is "notably above typical" with $1.2K (reported at a high percentile). The presence of high percentile chemotherapy/infusion administration codes signals that the practice bills for complex infusion encounters in addition to routine rheumatology injections.

Evaluation-and-management (E/M) revenue is small relative to drug revenue but shows concentrated severity: 99214 accounts for $44.9K (1.6%) and 99215 accounts for $34K (1.2%), with 99215 ranked in the 96th percentile nationally. This pattern—low share of total revenue from E/M but high percentile for complex visits—suggests a caseload focused on medically complex patients requiring intensive management alongside infusion therapies.

Tenure is long enough to support an established referral and operational structure: the NPI was enumerated on 2007-05-18 (~19 years ago). That duration is consistent with an experienced rheumatology practice capable of maintaining sustained biologic infusion services and relationships with payers and suppliers.

The absence of Medicaid billing ("none below — this provider has no Medicaid billing on file") means Medicaid exposure is effectively zero in the available data. For payers or risk analysts, that creates single‑payor concentration risk on Medicare reimbursement and may reflect limited Medicaid participation, alternative billing arrangements, or a patient panel skewed toward Medicare beneficiaries rather than dual‑eligible or Medicaid populations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	22,480	$30	$764.1K
J3245	Injection, tildrakizumab, 1 mg	6,800	$110	$748K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	145,200	$1	$580.8K
J0897	Injection, denosumab, 1 mg	9,840	$20	$177.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	13,650	$10	$150.2K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	5,270	$30	$147.5K
J3111	Injection, romosozumab-aqqg, 1 mg	9,870	$10	$79K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,090	$50	$56.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	560	$90	$52.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	510	$90	$44.9K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Elizabeth Perkins — 4 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3245	1	10	4,200	$110	$460.9K
J0129	3	30	8,530	$30	$390.9K
J0717	2	10	94,400	$1	$360.6K
J1602	12	20	16,100	$10	$189.5K
J3111	11	10	18,900	$10	$177.3K
Q5104	1	10	5,270	$30	$149K
J1745	20	30	3,020	$30	$107.2K
J0897	31	200	3,120	$20	$97.7K
96413	13	150	150	$90	$20.2K
99214	773	7,330	120	$80	$16.8K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Elizabeth Perkins, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lindsay Kelmenson	AL	Rheumatology Physician	$413.9K	$0

Nearby Providers

Other providers in the same ZIP code as Elizabeth Perkins, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Children's Hospital Of Alabama	AL	Pediatrics Physician	$0	$17.7M
Eh Health Hospice Of Alabama, LLC	AL	Community Based Hospice Care Agency	$0	$7.2M
Pediatric And Adolescent Dentistry, LLC	AL	Pediatric Dentistry	$0	$5.3M
Stratford Enterprises Inc	AL	Community Based Hospice Care Agency	$0	$4.7M
Medplex Pediatric Dentistry, Inc.	AL	Pediatric Dentistry	$0	$3.9M
William Thomas	AL	Pediatric Dentistry	$0	$2.1M
City Of Hoover	AL	Land Ambulance	$529.7K	$202K
Lauren Bannon	AL	Physician Assistant	$561.1K	$0
Diane Counce	AL	Neurology Physician	$501.8K	$0
Medplex Outpatient Surgery Center Ltd	AL	Ambulatory Surgical Clinic/Center	$366.4K	$0

Elizabeth Perkins — Billing Profile & Reimbursement Data

Sign up for Elizabeth Perkins — Billing Profile & Reimbursement Data policy alerts

Elizabeth Perkins — Billing Profile & Reimbursement Data

Sign up for Elizabeth Perkins — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References